Current location: Home > PRODUCTS > Next Generation Sequencing Series Products

PRODUCTS

Pan-Cancer Drive Gene Mutations Detection Kit

 (High Throughput Sequencing)

CE-IVD


Pan cancer driver gene mutation detection panel aims at the concomitant diagnostic genes approved by FDA and recommended by NCCN guidelines, covering 56 genes related to cancer treatment and prognosis, including 3000 cosmic mutation sites, so as to realize low-cost, high sensitivity and high-throughput gene detection of tumor tissue and blood free DNA of cancer patients.


  

Cell. 2018 Apr 5;173(2):305-320.e10.



Cancer is a complex polygenic disease caused by the gradual accumulation of gene mutations. When the genes regulating cell growth are mutated or damaged, the cells lose control and proliferate and differentiate disorderly and infinitely, leading to the occurrence of malignant tumors.


Tumor precise diagnosis and treatment products provide important reference basis for precise drug treatment, molecular typing and efficacy evaluation by accurately analyzing the unique gene mutation information of each tumor patient.


About NCI-MATCH

NCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial. In this trial, people with cancer are assigned to receive treatment based on the genetic changes found in their tumors through genomic sequencing and other tests. Genomic sequencing is a laboratory method that is used to determine the genetic makeup of cancer cells. People whose tumors have genetic changes that match one of the treatments in the trial may receive that treatment if they meet other eligibility criteria. The trial seeks to determine whether treating cancer based on these specific genetic changes is effective, no matter the cancer type.


Detection Content

    


Gene Mutation

EGFRKRASBRAFPIK3CAERBB2
METRB1ALKERBB4HNF1A
MPLSMAD4ATMFBXW7IDH1
SMOCDH1FGFR2JAK3NRAS
STK11CSF1RFLT3KDRTP53
ABL1GNASPTPN11AKT1GNAQ
MLH1RETAPCEZH2HRAS
NOTCH1SMARCB1FGFR1JAK2NPM1
SRCCDKN2AFGFR3IDH2PDGFRA
CTNNB1GNA11KITPTENVHL
ALKROS1RETNTRK1NTRK2
Gene FusionNTRK3



Gene 

Amplification

HER2MET


Note: ERBB2 and MET include copy number variation detection.



Detection Item

    

Product  NameSequencing PlatformNumber of AmpliconsTumor TypeSample Type

Human Pan-Cancer

Drive Gene Mutations 

Detection Kit 

Ion Torrent,

Illumina

  213 DNA amplicons, 

116 RNA fusion types

It covers solid tumors, 

blood tumors and 

hereditary tumors

Tumor tissue samples, 

peripheral blood or 

Pleural effusion 


Detection Significance

Personalized Medication: before using targeted drugs for malignant tumor patients, gene testing can be carried out to assist clinicians in judging the sensitivity of patients to drugs and evaluating the prognosis of patients.


Advantages and Features


Simple Operation: With patented RingCap® technology, library construction can be completed in only two steps.

Rapid Detection: Library construction takes only 3.5 hours.

High Sensitivity: The sensitivity can reach up to 1%.

Comprehensive Detection: 3000 kinds of cosmic mutation sites can be detected at one time.



Detection Process